We are live on ! Find out more

DexCom

DXCM

Market cap $31.5B

83.37 USD

-1.16

1.37%

At close Updated Sep 9, 9:44 AM EDT

1 day

-1.37%

5 days

-7.4%

1 month

-4.88%

3 months

6.62%

6 months

21.28%

Year to date

25.29%

1 year

6.34%

5 years

-39.66%

10 years

258.73%

About: DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.

Employees: 11,100

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 60%

Neutral 34%

Negative 6%

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

Technical indicators have turned bullish for the three stocks.

Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

Zacks Investment Research

Why DexCom (DXCM) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why DexCom (DXCM) is a Top Growth Stock for the Long-Term

Dexcom Announces Upcoming Conference Presentation

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. The live presentation is scheduled to begin at approximately 8:00 AM EDT and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. Dexcom em.

Dexcom Announces Upcoming Conference Presentation

Zacks Investment Research

Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.

Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?

Zacks Investment Research

Here's Why DexCom (DXCM) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why DexCom (DXCM) is a Strong Momentum Stock

The Big 3: PH, DXCM, UNP

Dan Deming discusses why he sees sideways action in the stock market continuing through next week, noting anticipating for the Fed's Jackson Hole meeting. As for Thursday's Big 3, he sees an opportunity in Parker-Hannifin (PH) closing its stock gap, Dexcom (DXCM) maintaining recent upward momentum, and Union Pacific (UNP) becoming a leader in the railroad industry's comeback.

The Big 3: PH, DXCM, UNP

Zacks Investment Research

Here's Why DexCom (DXCM) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why DexCom (DXCM) is a Strong Growth Stock

Zacks Investment Research

Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?

DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.

Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?

Zacks Investment Research

Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?

DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.

Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?

See News Rankings

Price charts implemented using Lightweight Charts™